Condensed Consolidated Statements of Earnings (Unaudited) - USD ($) shares in Millions, $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2025	Jun. 30, 2024	Jun. 30, 2025	Jun. 30, 2024
Income Statement [Abstract]
Net revenues	$ 15,423	$ 14,462	$ 28,766	$ 26,772
Cost of products sold	4,346	4,202	8,348	8,296
Selling, general and administrative	3,253	3,377	6,546	6,692
Research and development	2,131	1,948	4,198	3,887
Acquired IPR&D and milestones	823	937	1,071	1,101
Other operating income	24	0	24	0
Total operating costs and expenses	10,529	10,464	20,139	19,976
Operating earnings	4,894	3,998	8,627	6,796
Interest expense, net	678	506	1,305	959
Net foreign exchange loss	23	1	27	5
Other expense, net	2,639	1,345	4,080	1,931
Earnings before income tax expense	1,554	2,146	3,215	3,901
Income tax expense	613	773	985	1,156
Net earnings	941	1,373	2,230	2,745
Net earnings attributable to noncontrolling interest	3	3	6	6
Net earnings attributable to AbbVie Inc.	$ 938	$ 1,370	$ 2,224	$ 2,739
Per share data
Basic earnings per share (in dollars per share)	$ 0.52	$ 0.77	$ 1.25	$ 1.54
Diluted earnings per share (in dollars per share)	$ 0.52	$ 0.77	$ 1.24	$ 1.53
Weighted-average basic shares outstanding (in shares)	1,768	1,768	1,768	1,769
Weighted-average diluted shares outstanding (in shares)	1,771	1,771	1,772	1,772